Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 6/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28341854 | 0.86 | NNMT (0.49) | NNMTPIK3CBJAK2MAP4K4JAK1 | |
| SCHEMBL25841898 | 0.85 | NNMT (0.49) | NNMTPIK3CBPOLBJAK2MAP4K4 | |
| SCHEMBL1105936 | 0.82 | GABRP (0.47) | NNMTKMT2AGABRPGABRDGABRA1 | |
| SCHEMBL2085782 | 0.82 | NNMT (0.42) | NNMTNPSR1KMT2AGABRPGABRD | |
| SCHEMBL29198879 | 0.81 | GABRP (0.46) | NNMTKMT2AGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL22615201 | 0.81 | GABRP (0.46) | NNMTKMT2AGABRPGABRDGABRA1 | |
| SCHEMBL5009904 | 0.80 | NNMT (0.62) | NNMTPIK3CBPOLBMKNK1MKNK2 | |
| SCHEMBL30197143 | 0.80 | NNMT (0.62) | NNMTPIK3CBPOLBMKNK1MKNK2 | |
| SCHEMBL29799541 | 0.80 | NNMT (0.61) | NNMTJAK2JAK1TYK2JAK3 | |
| SCHEMBL384113 | 0.80 | NNMT (0.61) | NNMTJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
| US-7129234-B2 | Phenyl heterocyclyl ethers | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1377550-B9 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| CN-1656072-A | Phenyl heterocyclyl ether derivatives as 5-hydroxytryptamine reuptake inhibitors | PFIZER (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1377550-B1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| EP-1377550-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2002083643-A1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | NNMT 1533/4885PIK3CB 2385/4885POLB 4051/4885 |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | NNMT 2362/4885PIK3CB 1140/4885POLB 3236/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | NNMT 1533/4885PIK3CB 2385/4885POLB 4051/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | NNMT 1533/4885PIK3CB 2385/4885POLB 4051/4885 |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | NNMT 2362/4885PIK3CB 1140/4885POLB 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.